Meeting Banner
Abstract #2273

Minimum sample size requirements for rCBV measures in patient glioblastoma trials

Melissa A Prah 1 , Steven M Stufflebeam 2 , Eric S Paulson 1,3 , Jayashree Kalpathy-Cramer 2 , Elizabeth R Gerstner 4 , Tracy T Batchelor 4 , Daniel P Barboriak 5 , Bruce Rosen 2 , and Kathleen M Schmainda 1,6

1 Radiology, Medical College of Wisconsin, Milwaukee, WI, United States, 2 Radiology, Massachusetts General Hospital, Charlestown, MA, United States, 3 Radiation Oncology, Medical College of Wisconsin, Milwaukee, WI, United States, 4 Neurology, Massachusetts General Hospital, Boston, MA, United States, 5 Radiology, Duke University Medical Center, Durham, NC, United States, 6 Biophysics, Medical College of Wisconsin, Milwaukee, WI, United States

Measures of relative cerebral blood volume (rCBV) have shown to be immensely useful in assessing brain tumor vascularity. This has led to increased interest in the use of rCBV as a biomarker of clinical outcome or in research. This work provides an estimate of the minimum sample-size requirements to power a clinical imaging trial involving glioblastoma patients for six of the most commonly used rCBV estimation methods in order to detect a parameter change of 10% or 20%. Using these results, the efficiency of clinical trials may be improved with methods requiring considerably fewer participants to address a given hypothesis.

This abstract and the presentation materials are available to members only; a login is required.

Join Here